Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NZ and EU sign collaborative science agreement

This article was originally published in Scrip

Executive Summary

New Zealand and the EU have signed a science agreement which will expand New Zealand's collaboration with the European science community. The New Zealand/European Union Science and Technology Cooperation (STC) agreement will allow New Zealand researchers to enter EU programmes to which they previously would not have had access, in areas including plant, animal and medical science. Negotiations thus far have allowed New Zealand to participate in the EU's international research staff exchange scheme, which supports collaborations between institutions based in Europe and other countries. The new STC Agreement will begin once full ratification has been completed by the EU, expected at the end of this year. A joint New Zealand/EU committee will then meet regularly to identify shared research priorities.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC003287

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel